Patent Strategies and Competition Law in the Pharmaceutical Sector: Implications for Access to Medicines

Duncan Matthews, Olga Gurgula

Research output: Contribution to journalArticle

Abstract

Potentially anti-competitive practices, such as reverse payment agreements and strategic patenting, risk allowing pharmaceutical companies to block the entry of generic and innovative medicines, stifling competition and harming consumers. Such practices create particular challenges for developing countries. Policy coherence between the IP system and competition law must be strengthened in order to promote innovation and access to health technologies.
Original languageEnglish
Pages (from-to)661 - 667
JournalEuropean Intellectual Property Review
Volume38
Issue number11
Publication statusPublished - 16 May 2016

Fingerprint Dive into the research topics of 'Patent Strategies and Competition Law in the Pharmaceutical Sector: Implications for Access to Medicines'. Together they form a unique fingerprint.

Cite this